Huasun(SZ:000790)2023-05-10 10:18Group 1: Core Products and Market Coverage - The company's core products include over 30 varieties such as Sanqi Tongshu Capsules, Biyuan Shu Oral Liquid, and others [1] - Sanqi Tongshu Capsules cover 30 provinces in China, with key sales regions including Beijing, Sichuan, Shanghai, Jiangsu, Shandong, and Hubei [1] - The product is widely used in various medical departments, including neurology, cardiology, and traditional Chinese medicine, with plans to expand its application in cardiology this year [1] Group 2: Growth Potential and Market Strategy - The long-term growth of Sanqi Tongshu Capsules is expected to come from secondary development in new treatment areas, particularly in cardiology [2] - The company aims to restore its revenue levels to those of 2019, focusing on R&D investment, product line expansion, and strategic partnerships [3] - The company is actively pursuing the inclusion of its products in the new essential drug list, which would positively impact future business expansion [3] Group 3: Product Safety and Quality - Sanqi Tongshu Capsules utilize advanced purification technology to eliminate harmful residues, ensuring safety and compliance with EU drug safety standards [2] - The product has been recognized in the German Pharmacopoeia, marking a significant achievement in the internationalization of Chinese medicine [2] Group 4: Business Diversification and Future Plans - The company has integrated and acquired mineral water businesses to enhance its health industry strategy, focusing on C-end channels [4] - Plans are in place to consider the divestiture of the steel structure business due to its lack of synergy with the core pharmaceutical health business [4]